

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients with Severe Alopecia Areata with an Open-Label Extension Period

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Up to 18 years old

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- ages 12-17 - moderate to severe alopecia areata with at least 50% scalp hair loss - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- have a scalp condition, such as psoriasis or seborrheic dermatitis, that requires treatment - taking medications or other treatments that could affect hair growth or your immune system - women who are pregnant or breastfeeding - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:

Dermatology (Skin, Hair & Nails), Children's Health

Keywords:

Alopecia Areata, AA, hair loss

More Information

Description: The purpose of this study is to determine if deuruxolitinib is a safe and effective treatment for adolescents ages 12 to 17 with severe alopecia areata and at least 50% scalp hair loss.

Study Contact: Thomas Pritchard - prtc204@umn.edu

Principal Investigator: Maria Hordinsky

Phase: PHASE3

IRB Number: STUDY00025881

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.